N/A N=105 Young Adult EC Use and Respiratory Outcomes
E Cig Use
Primary: Spirometry to Measure the Change From Baseline in Forced Vital Capacity (FVC) — 4.42; 3.54; 4.61; 3.68 liter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Electronic Cigarette Use in Young Adult Men and Women
Cigarette Smoking · Tobacco Use
Primary: Contextual Factors Associated With Tobacco Use Episode Reported Via Ecological Momentary Assessment — 3; 22; 11; 12 tobacco use episodes — p=0.002
N/A N=45 Effects of Electronic Cigarette Settings and Liquid Concentrations in Cigarette Smokers and Electronic Cigarette Users
Electronic Cigarettes
Primary: Change in Plasma Nicotine — 8.68; 8.28; 9.53; 12.00 ng/ml
N/A N=187 Effects Among Smokers Who Use and Do Not Use E-Cigarettes
Toxicant Exposure
Primary: Toxicant Exposure — 40; 97 pg/ml
Early Phase 1 N=62 Responses to E-Cigarette Advertising
E-Cig Use
Primary: Attention to Specific ad Feature — -1.7062; -0.9676; -1.8238 Beats per minute
N/A N=68 A Trial of E-cigarettes in Current Cigarette Smokers
Smoking · Nicotine Dependence · Nicotine Dependence, Other Tobacco Product
Primary: Uptake of Electronic Nicotine Delivery Systems (ENDS) — 57.14; 32; 13.64 percentage of participants
N/A N=234 Changes in Biomarkers Associated With Use of Electronic Cigarettes
Biomarkers
Primary: Change in Biomarker Concentrations: Nicotine Equivalents — 74.9; 79.56 mmol/mg creatinine
N/A N=100 Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy
Tobacco Use Disorder · Smoking
Primary: Changes in the Number of Cigarettes Per Day (CPD) — 8.2; 7.3 cigarettes per day (CPD)
N/A N=31 JUUL vs. Mod E-cigarette Study
Smoking · Tobacco Use
Primary: Choices to Smoke — 26.15; 30; 38.33 Percentage of Total Choices
N/A N=38 Clinical Pharmacology of Electronic Cigarettes
Nicotine Dependence
Primary: Standardized Session: Mean CMax — 6.1; 20.2 ng/mL
N/A N=37 Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 2.2; 1.8; 6.0; 7.1 model estimated cigarettes per day
N/A N=350 Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures
Smoking, Cigarette
Primary: Proportion of Participants With Self-Reported 7-day Point Prevalence Abstinence From Cigarettes — 41; 33 Participants
N/A N=186 Responses to Regulated E-Cigarette Advertisements
Tobacco Use
Primary: Tobacco Use at 1 Month — 5; 5 Participants
N/A N=93 Impact of E-cigarette Characteristics on Reinforcement and Tobacco Use Patterns
Smoking · Tobacco Use
Primary: Mean Cigarettes Per Day — 13.1; 12.6; 12.2; 13.3 cigarettes per day
N/A N=33 Assessing Electronic Cigarette Nicotine Flux
Electronic Cigarette Use
Primary: Plasma Nicotine Concentration — 2.00; 1.92; 1.64; 1.62 mg/ml
N/A N=15 Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening
Electronic Cigarette Use · Smoking, Cigarette · Nicotine Dependence
Primary: Study Feasibility — 15 Participants
Phase 4 N=30 Effect of Electronic Cigarette Use on Cough Reflex Sensitivity
Cough
Primary: Change in Cough Reflex Sensitivity (Log C5) — -0.29; 0.24 log C5
N/A N=22 The Effect of Electronic Cigarette Liquid Characteristics in Smokers.
Electronic Cigarettes
Primary: Plasma Nicotine Concentration — 12.32; -0.22; 7.09; 5.85 ng/ml
N/A N=60 Predictors and Consequences of Combustible Cigarette Smokers' Switch to Standardized Research E-Cigarettes
Tobacco Use
Primary: Combustible Cigarette Use — 3.79; 3.64 Number of cigarettes smoked per day
N/A N=80 Low Nicotine Cigarettes Plus Electronic Cigarettes
Tobacco Dependence
Primary: Urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) — 505.6; 459.1; 373.3; 180.5 pg/mg creatinine — p=0.017
N/A N=638 Clinical Outcomes of a Nationwide, Naturalistic E-Cig Trial (CONNECT)
Smoking · Tobacco Use
Primary: E-cig Use at End of Sampling Period — 13; 72 percentage of participants
N/A N=450 E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease
Tobacco Use · E-Cigarette Use · Cardiovascular Diseases
Primary: Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge — 4.25; 4.89; 5.31 Percent change from resting diameter — p=.494
N/A N=372 Examination of Low Wattage and High Wattage E-Cigarettes
Smoking, Cigarette · Smoking, Tobacco · Nicotine Dependence
Primary: Complete Change From Conventional Cigarettes - Self Report — 0; 12; 10; 0 Participants
N/A N=2,896 Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes
Smoking Cessation
Primary: Rate of Smoking Abstinence — 33; 40; 37; 42 percentage of participants
Phase 2 N=40 Varenicline for Treatment of E-cigarette Dependence
Smoking Cessation
Primary: Number of Participants Abstinent From Vaping at Week 8 — 9; 6 Participants
N/A N=30 Effects of Electronic Cigarette Flavors on Abuse Liability in Smokers (P3-Taste)
Electronic Cigarette Use
Primary: Intensity of Drug Purchase Task (DPT) — 172.20; 89.90; 60.83; 94.50 number of puffs
N/A N=88 Evaluating E-Cigarette Nicotine Form, Concentration, and Flavors Among Youth
E-cigarette Use
Primary: Plasma Nicotine Concentration — 0.78; 1.08; 0.89; 1.16 ng/ml
N/A N=30 Quit or Switch: E-cigarette Study
Tobacco Use
Primary: Percentage of Participants Who Report Daily Use of E-cigarettes or NRT and no Cigarette Use
N/A N=27 Effects of Electronic Cigarettes on Nicotine Concentrations
Health Behavior
Primary: Effects E-cig Use on Venous Nicotine Concentrations Before and 5 Minutes After Use — 4.30; 4.11; 8.66; 8.77 ng/ml
N/A N=52 Impact of E-cigarette Nicotine Concentration on Compensation
Smoking Cessation
Primary: Total Inhaled Volume — 416.5; 490.3 mL